• Explore /
  • Poster
  • / The AFFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.

The AFFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.

Abstract Poster

Authors

null

Sagar Lonial

Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

Sagar Lonial , Michel Delforge , Hermann Einsele , Philippe Moreau , Martin Kaiser , Meletios A. Dimopoulos , Albert Oriol , Martin Gyger , Brandi Hilder , Ann M. Ptaszynski , Roger Aitchison , Robert Z. Orlowski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT02092922

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS8613)

DOI

10.1200/jco.2015.33.15_suppl.tps8613

Abstract #

TPS8613

Poster Bd #

425a

Abstract Disclosures

Similar Posters

First Author: Andrew J Yee

First Author: Andrew Jenho Yee

First Author: David Samuel DiCapua Siegel

First Author: Cristina Gasparetto